Pluristem Therapeutics (NASDAQ:PSTI) Stock Price Up 11.7%

Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) rose 11.7% during trading on Friday . The company traded as high as $5.37 and last traded at $5.06, approximately 101,576 shares traded hands during mid-day trading. An increase of 111% from the average daily volume of 48,124 shares. The stock had previously closed at $4.53.

PSTI has been the subject of a number of research reports. LADENBURG THALM/SH SH downgraded Intec Pharma from a “buy” rating to a “neutral” rating in a research note on Monday. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. ValuEngine downgraded Welbilt from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Maxim Group reiterated a “buy” rating and set a $315.00 price objective (up from $305.00) on shares of Domino’s Pizza in a research report on Wednesday, April 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Pluristem Therapeutics has an average rating of “Buy” and an average price target of $31.88.

The company has a 50-day moving average of $0.74. The firm has a market cap of $660.03 million, a price-to-earnings ratio of -20.24 and a beta of 0.92.

Pluristem Therapeutics (NASDAQ:PSTI) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.20). As a group, equities analysts forecast that Pluristem Therapeutics Inc. will post -0.31 earnings per share for the current year.

A number of large investors have recently made changes to their positions in PSTI. Nikko Asset Management Americas Inc. bought a new stake in Pluristem Therapeutics during the first quarter worth approximately $900,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in Pluristem Therapeutics during the first quarter worth approximately $881,000. ARK Investment Management LLC raised its holdings in Pluristem Therapeutics by 12.0% during the first quarter. ARK Investment Management LLC now owns 3,793,249 shares of the biotechnology company’s stock worth $3,679,000 after purchasing an additional 406,155 shares in the last quarter. Finally, Virtu Financial LLC raised its holdings in Pluristem Therapeutics by 266.1% during the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 61,858 shares in the last quarter. 6.00% of the stock is currently owned by hedge funds and other institutional investors.

About Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also: Why do companies pay special dividends?

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.